Expression and therapy of Prame gene on hematologic malignancies

doi:10.3760/cma.j.issn.1673-422X.2014.08.017

Abstract

Abstract: As a member of the family of cancertestis antigen, preferentially expressed antigen of melanoma (Prame) can improve the proliferation of tumor via inhibiting the retinoic acid receptor signal path and impeding the transcription factor which is a wide range of physiological processes in development and differentiation of tumor cells. Prame expresses in solid tumors and hematological malignancies, which is widely used for tumor diagnosis, monitoring of tumor metastasis and immunotherapy.

Key words: Hematologic neoplasms, Immunotherapy, Preferentially expressed antigen of melanoma

Liu Zhaoyun. Expression and therapy of Prame gene on hematologic malignancies[J]. Journal of International Oncology, 2014, 41(8): 611-614.

References

［1］ Ikeda H, Lethé B, Lehmann F, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor［J］. Immunity,1997, 6(2): 199-208. ［2］ Schenk T, Stengel S, Goellner S, et al. Hypomethylation of PRAME is responsible for its aberrant overexpression in human malignancies［J］. Genes Chromosomes Cancer, 2007, 46(9): 796-804. ［3］ Epping MT, Wang L, Edel MJ, et al. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling［J］. Cell, 2005, 122(6): 835-847. ［4］ Matsushita M, Ikeda H, Kizaki M, et al. Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia［J］. Br J Haematol, 2001, 112(4): 916-926. ［5］ ProtoSiqueira R, FigueiredoPontes LL, Panepucci RA, et al. PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma［J］. Leuk Res, 2006, 30(11): 1333-1339. ［6］ Spanaki A, Perdikogianni C, Linardakis E, et al. Quantitative assessment of PRAME expression in diagnosis of childhood acute leukemia［J］. Leuk Res, 2007, 31(5): 639-642. ［7］ Steinbach D, Viehmann S, Zintl F, et al. PRAME gene expression in childhood acute lymphoblastic leukemia［J］. Cancer Genetics Cytogenet, 2002, 138(1): 89-91. ［8］ van den Ancker W, Ruben JM, Westers TM, et al. Priming of PRAME and WT1specific CD8+ T cells in healthy donors but not in AML patients in complete remission: implications for immunotherapy［J］. Oncoimmunology, 2013, 2(4): e23971. ［9］ Lynch RG, Graff RJ, Sirisinha S, et al. Myeloma proteins as tumorspecific transplantation antigens［J］. Proc Natl Acad Sci USA, 1972, 69(6): 1540-1544. ［10］ Crainie M, Belch AR, Mant MJ, et al. Overexpression of the receptor for hyaluronanmediated motility (RHAMM) characterizes the malignant clone in multiple myeloma: identification of three distinct RHAMM variants［J］. Blood, 1999, 93(5): 1684-1696. ［11］ Qian J, Xie J, Hong S, et al. Dickkopf1 (DKK1) is a widely expressed and potent tumorassociated antigen in multiple myeloma［J］. Blood, 2007, 110(5): 1587-1594. ［12］ Abramenko IV, Belous NI, Kriachok IA, et al. Expression of PRAME gene in multiple myeloma［J］. Ter Arkh, 2004, 76(7): 77-81. ［13］ Qin YZ, Zhu HH, Liu YR, et al. PRAME and WT1 transcripts constitute a good molecular marker combination for monitoring minimal residual disease in myelodysplastic syndromes［J］. Leuk Lymphoma, 2013, 54(7): 1442-1449. ［14］ Staege MS, BanningEichenseer U, Weissflog G, et al. Gene expression profiles of Hodgkin′s lymphoma cell lines with different sensitivity to cytotoxic drugs［J］. Exp Hematol, 2008, 36(7): 886-896. ［15］ Kewitz S, Staege MS. Knockdown of PRAME increases retinoic acid signaling and cytotoxic drug sensitivity of Hodgkin lymphoma cells［J］. PLoS One, 2013, 8(2): e55897. ［16］ Beà S, Salaverria I, Armengol L, et al. Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution wholegenome profiling［J］. Blood, 2009, 113(13): 3059-3069. ［17］ Paydas S, Tanriverdi K, Yavuz S, et al. PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects［J］. Am J Hematol, 2005, 79(4): 257-261. ［18］ Perna SK, De Angelis B, Pagliara D, et al. Interleukin 15 provides relief to CTLs from regulatory T cellmediated inhibition: implications for adoptive T cellbased therapies for lymphoma［J］. Clin Cancer Res, 2013, 19(1): 106-117. ［19］ Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following nonmyeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma［J］. J Clin Oncol, 2005, 23(10): 2346\-2357. ［20］ Colombo MP, Piconese S. RegulatoryTcell inhibition versus depletion: the right choice in cancer immunotherapy［J］. Nat Rev Cancer, 2007, 7(11): 880-887. ［21］ Cerundolo V, Hermans IF, Salio M. Dendritic cells: a journey from laboratory to clinic［J］. Nat Immunol, 2004, 5(1): 7-10. ［22］ Li L, Giannopoulos K, Reinhardt P, et al. Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts［J］. Int J Oncol, 2006, 28(4): 855-861. ［23］ Weber G, Caruana I, Rouce RH, et al. Generation of tumor antigenspecific T cell lines from pediatric patients with acute lymphoblastic leukemiaimplications for immunotherapy［J］. Clin Cancer Res, 2013, 19(18): 5079-5091. ［24］ Yong AS, Keyvanfar K, Eniafe R, et al. Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemiaassociated antigens: implications for the graftversusleukemia effect and peptide vaccinebased immunotherapy［J］. Leukemia, 2008, 22(9): 1721-1727. ［25］ Kessler JH, Khan S, Seifert U, et al. Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes［J］. Nat Immunol, 2011, 12(1): 45-67. ［26］ Tabarkiewicz J, Giannopoulos K. Definition of a target for immunotherapy and results of the first Peptide vaccination study in chronic lymphocytic leukemia［J］. Transplant Proc, 2010, 42(8): 3293-3296. ［27］ Griffioen M, Kessler JH, Borghi M, et al. Detection and functional analysis of CD8+ T cells specific for PRAME: a target for Tcell therapy［J］. Clin Cancer Res, 2006, 12(10): 3130-3136. ［28］ Weber JS, Vogelzang NJ, Ernstoff MS, et al. A Phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostatespecific membrane antigen in patients with advanced solid tumors［J］. J Immunother, 2011, 34(7): 556-567. ［29］ Bullinger L, Schlenk RF, Gtz M, et al. PRAMEinduced inhibition of retinoic acid receptor signalingmediated differentiationa possible target for ATRA response in AML without t(15;17)［J］. Clin Cancer Res, 2013, 19(9): 2562-2571.

[1]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[2]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[3]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[4]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[5]	Yang Hao, Shi Guidong, Zhang Chengcheng, Zhang Yue, Zhang Liwen, Fu Maoyong. Comparison of efficacy and safety between sintilimab and tislelizumab in neoadjuvant therapy for advanced esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(4): 210-216.
[6]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[7]	Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao. Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes [J]. Journal of International Oncology, 2024, 51(3): 143-150.
[8]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[9]	Teng Yuan, Li Lijuan, Zhang Liansheng. Progress of MCL-1 and its inhibitors in hematologic malignancies [J]. Journal of International Oncology, 2024, 51(2): 119-122.
[10]	Cui Tenglu, Lyu lu, Sun Pengfei. Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(9): 548-552.
[11]	Wang Jun, Rong Lei, Huang Jing, Meng Jingye, Guo Zhi. Diagnostic value of transbronchial lung biopsy and bronchoalveolar lavage in pulmonary complications in patients with hematological tumors [J]. Journal of International Oncology, 2023, 50(7): 419-424.
[12]	Guo Ciliang, Jiang Chunping, Wu Junhua. Gut microbiome and tumor immunotherapy [J]. Journal of International Oncology, 2023, 50(7): 432-436.
[13]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[14]	Lyu Lu, Sun Pengfei. Gut flora and cervical cancer [J]. Journal of International Oncology, 2023, 50(6): 373-376.
[15]	Gu Anqin, Long Jinhua, Jin Feng. Clinical research progress of immunotherapy for nasopharyngeal carcinoma [J]. Journal of International Oncology, 2023, 50(5): 299-303.